TCTMD’s Top 10 Most Popular Stories for August 2017

Breaking news from the European Society of Cardiology (ESC) Congress 2017—from DETO2X-AMI, COMPASS, and CANTOS, among other trials—topped the charts on TCTMD this month, as did Managing Editor Shelley Wood’s preview ahead of the meeting. Other hits were a feature article on 3-D printing in structural heart disease, news that one company is scrapping its bioresorbable scaffold program, and a study exploring the use of fibrinolytic agents for STEMI.

You can check out all our ESC Congress 2017 coverage here.

Supplemental Oxygen Provides No Benefit to Patients With Suspected MI: DETO2X-AMI

Don’t waste time with oxygen. Focus instead on getting patients to the cath lab as quickly as possible, says one expert.

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

The trial “should change guidelines for the management of chronic stable coronary artery disease,” Eugene Braunwald says.

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

The Barcelona attack just 9 days before the Congress opened left organizers hastening to insist that the show must go on and big trials were still in the offing.

A Heart to Hold: 3-D Printers Add New Dimension to the Treatment of Structural Cardiac Disease

The fast-evolving technology is poised to shake up cardiac interventions, but training, guidelines, reimbursement, and regulatory oversight lag behind.

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Signals of harm warrant further study, but experts seem excited at the idea of exploring hitherto unmapped pathways in CVD progression.

Renal Denervation: Proof-of-Concept Study Gives Fresh Jolt to Fizzled Field

In SPYRAL HTN-OFF MED, more intensive denervation lowered blood pressure, warranting larger, more definitive trials, experts say.

Boston Scientific Scraps Biodegradable Scaffold Program

The thinner-strut Renuvia scaffold won’t be studied any further based on discouraging results Abbott’s Absorb BVS, the company confirmed.

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

The findings might help guide development of systems of care in the developing world, one expert says.

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

The RE-DUAL PCI findings provide a compelling reason to move away from traditional triple therapy with warfarin, Spencer King says.

ESC Updates Guidelines for Treating STEMI Patients

The updated recommendations, designed to be reader-friendly, emphasize radial access and complete revascularization, among other changes.